Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human trial of lassa fever pill shows promise in safety check

NCT ID NCT05735249

First seen May 03, 2026 · Last updated May 23, 2026 · Updated 3 times

Summary

This early-stage study tested a new oral drug called ARN-75039, being developed to treat Lassa fever, a serious viral illness. The trial involved 94 healthy adults to check the drug's safety and how the body processes it. Participants received either the drug or a placebo in single or multiple doses. The goal was to see if the drug is safe enough to move into future studies with infected patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Spaulding Clinical, LLC

    West Bend, Wisconsin, 53095, United States

Conditions

Explore the condition pages connected to this study.